Indian pharma’s cold reply to China call


The Hindu

Indian pharma’s cold reply to China call

Dated March 23, 2019  

Firms shrug off Yunnan’s proposal to source Indian drugs; lengthy process cited

A call for expression of interest from Indian pharma companies desirous of supplying medicines to a Chinese province has met with lukewarm response, something which is bound to turn the spotlight on the regulatory approval process in China.

There has not been one response thus far, Pharmaceuticals Export Promotion Council of India Director General Ravi Udaya Bhaskar said late on Friday, when a deadline for the companies to respond to the Yunnan province’s call ended. A few companies had, however, sought to know the list of products the province wanted to source, he said. Pharmexcil, a body under the Commerce Ministry, had recently sounded out member-firms about the opportunity, in the wake of the Director General of Yunnan Provincial Foreign Affairs informing the Consulate General of India in Guangzhou about the province’s interest to introduce Indian drugs to the city and the provincial health system.

Indian pharma firms were asked to submit a list of products they can supply to Yunnan, along with certifications such as those from the U.S. Food and Drug Administration (USFDA), if any.

The response may have been better had the companies been provided with a list of products Yunnan planned to source, Mr. Bhaskar said. Lack of information as well as the regulatory process in China, especially the time taken for product registration, were issues behind the level of response, he added.

Three to five years is the norm for getting a product registration from China’s National Medical Products Administration (NMPA) and this comes to about $58,000 per drug. Also, this is not the first instance of such a tepid response from pharma firms — they did not evince much interest when opportunities in Guiyang City were highlighted.

Thus, Pharmexcil is keen on stepping up its efforts to pursue the Chinese government to fast track the registration and medicines procurement process from India. The Council is also working with the China Chamber of Commerce of Import and Export of Medicines and Health Products.

Such an emphasis comes in the backdrop of the potential to grow pharma exports to China. In 2017-18, pharma exports to China rose 37% to $200 million, an increase of over 37% from the $145 million of the previous fiscal. Aurobindo Pharma, Dr.Reddy’s Laboratories, Lupin, Hetero are some of the companies already doing business in China. The exports are set to grow this fiscal too, with the $185 million mark crossed in January, but at the pace could be faster, he said.


Link https://www.thehindu.com/business/Industry/indian-pharmas-cold-reply-to-china-call/article26621311.ece

Comments

Post a Comment

Popular posts from this blog

India Joins Russia in Voting Against West-Backed Move to Expand Powers of OPCW

The Wire: June 28, 2018 New Delhi: India voted against a UK-backed move that will allow the global chemical weapons watchdog to apportion blame for illegal attacks, criticising the decision to grant “unchecked powers” to the head of the group which could be used for “partisan” purposes. On Wednesday, more than two-thirds of the member states of the Organisation for the Prohibition of Chemical Weapons (OPCW) voted to authorise the international body to identify the perpetrators and sponsors of a chemical weapons attack. It also specifically called on the OPCW’s technical secretariat to begin work on identifying the perpetrators behind the use of chemical weapons in Syria. The draft decision, sponsored by 30 countries, was adopted at the fourth special session of the conference of the states parties to the Chemical Weapons Convention at the Hague, with 82 in favour and 24 negative votes. While Europe, the United States and their allies voted ‘yes’, there was strong oppo...
Read more

As financial insecurity rises in urban India, so does investment in insurance

Image
Scroll.in March 13, 2020 Urban Indians are becoming less confident about their financial security. Up to 58% of them fret over financial independence post retirement, which is a 4% increase from last year. An equal share of urban Indians worry about meeting their daily medical expenses and sustaining their current lifestyle once they stop working. The findings are part of a survey published by Delhi-based Max Life Insurance in association with London-based consultancy Kantar. The firms surveyed 7,014 respondents in 25 cities, including six metros, nine tier-1 cities, and 10 tier-2 cities, between December 2019 and January 2020. Source: Max Life Insurance via Quartz The trends Source: Max Life Insurance via Quartz Source: Max Life Insurance via Quartz Source: Max Life Insurance via Quartz A significant share of urban Indians also say their families will have no financial support in the event of the breadwinner’s death. In such a scenario, around 57% believe the family sav...
Read more

ED tracks Swiss Bank A/Cs of Agusta scamster

The Poineer February 10,2019 Rakesh K Singh The Enforcement Directorate (ED) has tracked a dozen Swiss bank accounts in the name of Rajiv Saxena, who is key accused in the Rs 3,600 crore AgustaWestland VVIP chopper scam. The ED has also found out accounts held by  his family members and associates where the kickbacks in the now scrapped deal were allegedly parked. Two bank accounts are in the name of Rajiv Saxena’s  associates Pankaj Jain and Sumita Jain who are also the authorised signatories. The  third is in the name of another associate Ajit Singh Bubber, but Rajiv and his family members are authorised signatories. The remaining nine accounts are largely owned and operated by Rajiv, his family members and associates. Rajiv Saxena was deported by the UAE authorities on January 30 and the ED formally arrested him the next day and a court later granted his remand to the agency. He is currently undergoing custodial interrogation by the ED. The agency had in 2017...
Read more